Stifel cuts cannabis industry view as analysts weigh Tilray

Stifel reiterated sell ratings on Aurora Cannabis ACB, +3.59% ACB, +3.63% and Canopy Growth CGC, +5.95% WEED, +5.26% because of an “increasingly difficult Canadian market.” The brokerage cut its Aurora Cannabis price target to C$3.00 from C$3.50 and trimmed Canopy Growth’s price target to C$6 from C$7.50.

Cannabis software maker WM Technology Inc. MAPS, +1.90% stands out as “the best positioned” cannabis name to capitalize on category growth, with shares that continue to undervalue a “robust” growth outlook, he said. WM Technology’s price target was reduced by $1 to $10 a share.

Carter also remains “increasingly positive” on Altria Group Inc. MO, -0.34% -backed Cronos Group Inc. CRON, +3.64% CRON, +3.62% on strength in its Spinach cannabis business, as well as accessories seller GrowGeneration Corp. GRWG, +9.14% on its supply chain skills. Cronos’s price target was set at $4 a share, while GrowGeneration’s price target was trimmed to $8.50 a share from $9.

Stifel shaved its 2022 earnings view on ScottsMiracle-Gro Co. SMG, +2.03% to $7.31 a share from $8.02 a share on weakness in its Hawthrorne hydroponics business and an overall recession in the business. Stifel cut its price target on the company to $130 a share from $160 a share.

“We now estimate a less fulsome recovery for Hawthorne… given colder weather, and higher input costs,” Carter said. “But with our reductions, we believe the earnings growth profile remains undervalued.”

Also Read: Scotts Miracle-Gro-backed RIV Capital buying New York cannabis company Etain

Stifel cut its Hydrofarm Holdings Group Inc.’s HYFM, +2.62% 2022 revenue estimate to $573 million from $595 million as it competes with promotional efforts from Hawthorne. Stifel slashed its Hydrofarm price target to $13 a share from $33.

Shares of Hydrofarm Holding are down 65.8% in 2022, but the stock rose 1.7% on Monday. Scotts Miracle-Gro shares rose 3.7% on Monday, but the stock has lost 33% so far this year.

Meanwhile, Alliance Global Partners analyst Aaron Grey on Monday cut his target price on Tilray TLRY, +5.16% TLRY, +5.02% to $5.50 a share from $8.00 and reiterated a neutral rating on the stock after the company held an analyst day last week.

Although the company reiterated its plan to grow revenue to $4 billion in 2024 from about $630 million in 2022, that path “embeds a number of factors outside its control” such as the legalization of adult use cannabis in the U.S. and Germany and “more rational” market conditions in Canada, Grey said.

While reaching $4 billion “could prove a difficult task” without acquisitions beyond those already embedded, Tilray offers some bright spots, such as 12 consecutive quarters of Ebitda and positive cash flow on the horizon, plus its strategy of adding “self-sustaining” businesses in the U.S. such as its beverages as it awaits catalysts for more growth, Grey said.

Shares of Tilray rose 2% on Monday. The stock is down 27.7% so far this year.

Overall, stock performance in the cannabis sector remains weak. The AdvisorShares Pure Cannabis ETF MSOS, -0.13% has lost 41.2% of its value in 2022, compared to a drop of 20.3% by the Nasdaq. The Cannabis ETF THCX, +0.70% has dropped 33.4% so far in 2022.

Also Read: Investors in cannabis companies burned by stock-market losses in 2021 even as the pot business grows